|
|
| | Tulobuterol hydrochloride Basic information |
| | Tulobuterol hydrochloride Chemical Properties |
| Melting point | 159-163℃ | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | color | White | | Water Solubility | Soluble in methanol or water. | | Sensitive | Hygroscopic | | Merck | 14,9811 | | Major Application | forensics and toxicology
pharmaceutical (small molecule)
veterinary | | InChI | 1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H | | InChIKey | RSLNRVYIRDVHLY-UHFFFAOYSA-N | | SMILES | Cl.CC(C)(C)NCC(O)c1ccccc1Cl | | CAS DataBase Reference | 56776-01-3(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | RTECS | DN8785000 | | HS Code | 2922.19.7000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Tulobuterol hydrochloride Usage And Synthesis |
| Uses | Hydrochloride salt of Tulobuterol a sympathomimetic drug used as a transdermal patch, increases normal diaphragm muscle strength. A β-adrenergic receptor agonist, related structurally to Terbutaline (T109750). | | Uses | Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength. Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation. | | Definition | ChEBI: Tulobuterol hydrochloride is an organic molecular entity. | | General Description | Standard for Supelco MIP SPE cartridges. For more information request Supelco Literature T407075, T706019, T706030, T706020 | | in vivo | In vivo effect of Tulobuterol is examined the on the contractility of diaphragm muscles prepared from mice (BALBs/c mice; 21.7 ± 0.2 g) treated with Endotoxin. Contractile parameters of force-frequency curves and twitch kinetics using untreated or treated diaphragm muscles at 0 (E0) and 4 (E4) hours after E. coli endotoxin (20 mg/kg) administration are measured. E0 and E4 diaphragm muscles are analyzed at 0, 12, and 24 h after transdermal Tulobuterol treatment. The force-frequency curves of E0 and E4 diaphragm muscles at three time points are not significantly changed each other, indicating that Tulobuterol patch restores the muscle contractility. Thus, diaphragm muscle contractility is maintained during 4 h of endotoxin administration with Tulobuterol patch for over 24 h[3]. |
| | Tulobuterol hydrochloride Preparation Products And Raw materials |
|